Bydureon Bcise OverviewExenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, ...
Read more Bydureon Bcise Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Byetta
Recent Bydureon Bcise Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- For Suspension, Extended Release: 2mg, 2mg/vial
- Injection: 2mg, 300mcg/1.2ml (250mcg/ml), 300ugm/1.2ml (250ugm/ml), 300ugm/1.2ml(250ugm/ml), 600mcg/2.4ml (250mcg/ml), 600ugm/2.4ml (250ugm/ml), 600ugm/2.4ml(250ugm/ml)
- Suspension, Extended Release: 2mg/0.85ml (2mg/0.85ml)
NDC Database Records for Bydureon Bcise: (1 result)Sorted by National Drug Code
- 0310-6540 Bydureon Bcise 2 mg/.85ml Subcutaneous Injection, Suspension, Extended Release by Astrazeneca Pharmaceuticals Lp